Evidence map›Paper›PMID 39243787›Full record

ArticleThe lancet. HIV2024

Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, open-label, multicentre study.

Mayara Secco Torres Silva, Thiago Silva Torres, Carolina Coutinho, Ronaldo Ismério Moreira, Iuri da Costa Leite, Marcelo Cunha, Pedro Henrique Amparo da Costa Leite, Carlos F Cáceres, Hamid Vega-Ramírez, Kelika A Konda and 9 more

Abstract readMulticenter Study
In one paragraph

Article in The lancet. HIV, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Mayara Secco Torres SilvaInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro, Brazil.
Thiago Silva TorresInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro, Brazil.
Carolina CoutinhoInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro, Brazil.
Ronaldo Ismério MoreiraInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro, Brazil.
Iuri da Costa LeiteEscola Nacional de Saúde Pública Sérgio Arouca, Fundação Oswaldo Cruz (ENSP-Fiocruz), Rio de Janeiro, Brazil.
Marcelo CunhaEscola Nacional de Saúde Pública Sérgio Arouca, Fundação Oswaldo Cruz (ENSP-Fiocruz), Rio de Janeiro, Brazil.
Pedro Henrique Amparo da Costa LeiteEscola Nacional de Saúde Pública Sérgio Arouca, Fundação Oswaldo Cruz (ENSP-Fiocruz), Rio de Janeiro, Brazil.
Carlos F CáceresUniversidad Peruana Cayetano Heredia, Centro de Investigaciones Interdisciplinarias en Salud, Sexualidad, y SIDA, Lima, Peru.
Hamid Vega-RamírezInstituto Nacional de Psiquiatria Ramón de la Fuente Muñiz, Mexico City, Mexico.
Kelika A KondaUniversidad Peruana Cayetano Heredia, Centro de Investigaciones Interdisciplinarias en Salud, Sexualidad, y SIDA, Lima, Peru; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Juan GuaniraUniversidad Peruana Cayetano Heredia, Centro de Investigaciones Interdisciplinarias en Salud, Sexualidad, y SIDA, Lima, Peru.
José Valdez MadrugaCentro de Referência e Treinamento em DST/AIDS-CRT-SP, São Paulo, Brazil.
Sandra Wagner CardosoInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro, Brazil.
Marcos BenedettiInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro, Brazil.
Maria Cristina PimentaInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro, Brazil.
Brenda HoaglandInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro, Brazil.
Beatriz GrinsztejnInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro, Brazil. Electronic address: gbeatriz@ini.fiocruz.br.
Valdilea Gonçalves VelosoInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (INI-Fiocruz), Rio de Janeiro, Brazil.
ImPrEP Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe global burden of sexually transmitted infections (STIs) poses a challenge in the context of HIV pre-exposure prophylaxis (PrEP) programmes. We aimed to explore factors associated with prevalent, incident, and recurrent STIs in men who have sex with men (MSM) and transgender women on PrEP in Brazil, Mexico, and Peru.

methodsImPrEP was a prospective, single-arm, open-label, multicentre study that enrolled MSM and transgender women in the context of the public health systems of Brazil (14 sites), Mexico (four sites), and Peru (ten sites) between February, 2018, and June, 2021. Eligibility criteria followed regional PrEP guidelines at the study start, including participants aged 18 years and older, not living with HIV, and reporting at least one of the following in the previous 6 months: condomless anal sex (CAS), anal sex with partner(s) living with HIV, any bacterial STI, or transactional sex. Eligible participants were screened and enrolled on the same day to receive daily oral PrEP (tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg). We assessed three outcomes: prevalent bacterial STIs, incident bacterial STIs, and recurrent bacterial STIs. Testing occurred at baseline and quarterly for syphilis, anorectal chlamydia, and anorectal gonorrhoea. Behavioural data were collected at baseline and quarterly. The study was registered with the Brazilian Registry of Clinical Trials, U1111-1217-6021.

findingsAmong all 9509 participants included in the ImPrEP study (3928 [41·3%] in Brazil, 3288 [34·6%] in Mexico, and 2293 [24·1%] in Peru), 8525 (89·7%) had available STI results at baseline and were included in the prevalent STI analysis, and 7558 (79·5%) had available STI results during follow-up and were included in the incident and recurrent STI analyses. 2184 (25·6%) of 8525 participants had any bacterial STI at baseline. STI incidence during follow-up was 31·7 cases per 100 person-years (95% CI 30·7-32·7), with the highest rate for anorectal chlamydia (11·6 cases per 100 person-years, 95% CI 11·0-12·2), followed by syphilis (10·5 cases per 100 person-years, 9·9-11·1) and anorectal gonorrhoea (9·7 cases per 100 person-years, 9·2-10·3). Although only 2391 (31·6%) of 7558 participants had at least one STI during follow-up, 915 (12·1%) participants had recurrent diagnoses, representing 2328 (61·2%) of 3804 incident STI diagnoses. Characteristics associated with prevalent, incident, and recurrent STIs included younger age, multiple sex partners, receptive CAS, substance use, and previous STI diagnoses at baseline (incident or recurrent only).

interpretationOur findings underscore the nuanced dynamics of STI transmission among MSM and transgender women across Latin America, highlighting an urgent need for tailored interventions to mitigate STI burden effectively, especially among the most susceptible individuals.

fundingUnitaid, WHO, and ministries of health (Brazil, Mexico, and Peru). TRANSLATIONS: For the Portuguese and Spanish translations of the abstract see Supplementary Materials section.

Indexed as

Homosexuality, MalePre-Exposure ProphylaxisTransgender PersonsAdolescentAdultAnti-HIV AgentsBrazilFemaleHIV InfectionsHumansIncidenceMaleMexicoPeruPrevalenceProspective StudiesAnti-HIV Agents

Identifiers

PMID39243787
PMCPMC11442320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.